NAD+ vs NMN: coenzyme vs precursor
NAD+ vs NMN is one of the most searched comparisons in longevity research. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme itself — present in every cell, required for energy metabolism and consumed by sirtuins and PARP enzymes. NMN (nicotinamide mononucleotide) is a precursor: cells convert it into NAD+ through the salvage pathway. Animal studies report that NAD+ levels decline with age, which is why both molecules are studied in aging and metabolism research. PeptidesDirect supplies NAD+ as ≥99% purity lyophilised powder for laboratory research use only; we do not sell NMN.
Side-by-side comparison
| NAD+ | NMN | |
|---|---|---|
| What it is | Dinucleotide coenzyme — the active molecule cells use | Nucleotide precursor — converted into NAD+ inside cells |
| Role | Carries electrons in energy metabolism; substrate for sirtuins and PARPs | Intermediate in the NAD+ salvage pathway |
| Molecular weight | 663.43 g/mol | 334.22 g/mol |
| Research focus | Direct replenishment of cellular NAD+ in lab models | Raising NAD+ indirectly via oral precursor administration |
| Sold by PeptidesDirect | Yes — 100mg and 750mg vials, research use only | No |
What is NAD+?
NAD+ is a dinucleotide coenzyme found in every living cell. It shuttles electrons in the reactions that convert nutrients into cellular energy, and it is consumed as a substrate by sirtuins and PARP enzymes, linking it to DNA repair and cellular stress responses (Verdin, 2015).
Despite being stocked by peptide suppliers, NAD+ is not a peptide — it contains no amino acids. It is two nucleotides joined by a phosphate bridge.
How NMN relates to NAD+
Cells make NAD+ through the salvage pathway, and NMN is the immediate precursor in that pathway: the enzyme NMNAT converts NMN into NAD+. Giving NMN is therefore an indirect way of raising NAD+ levels, studied mostly in oral administration models.
In mice, long-term NMN administration mitigated age-associated physiological decline across several measures (Mills et al., 2016). In humans, a safety study in healthy Japanese men reported that oral NMN was tolerated and raised nicotinamide metabolite levels (Irie et al., 2020), and a randomised trial in prediabetic women reported increased muscle insulin sensitivity (Yoshino et al., 2021).
Why researchers compare them
The practical question in the literature is whether to supply the coenzyme directly or supply a precursor and let the cell convert it. NAD+ itself is a larger, charged molecule, so much of the oral-supplement literature favours precursors; direct NAD+ is widely used in laboratory and in-vitro work where delivery is controlled.
A 2018 Cell Metabolism review summarised the in-vivo evidence for NAD-boosting molecules, most of it generated with precursors such as NMN and nicotinamide riboside (Rajman et al., 2018).
Frequently asked questions
What is the difference between NAD+ and NMN?
NAD+ is the coenzyme cells actually use; NMN is a precursor that cells convert into NAD+ through the salvage pathway. They are different molecules with different roles in research.
Is NMN a peptide?
No. Like NAD+, NMN is a nucleotide, not a peptide. Neither contains amino acids.
Which has more human research, NAD+ or NMN?
Most published human trials have used precursors such as NMN and nicotinamide riboside rather than NAD+ itself. Direct NAD+ is more common in laboratory and in-vitro research.
Does PeptidesDirect sell NMN?
No. We supply NAD+ in 100mg and 750mg vials for laboratory research only. See our research peptides guide (/learn/research-peptides) for how to compare suppliers and read test documents.
How should NAD+ be stored?
Keep lyophilised NAD+ cold, dry and protected from light; refrigerate reconstituted solutions. See our research peptides guide (/learn/research-peptides) for how to compare suppliers and read test documents.
Is this product for human use?
No. PeptidesDirect sells this compound for laboratory research only. It is not a drug, food or cosmetic and is not for human or veterinary use. This page summarises published research and is not dosing or medical guidance.
References
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015. PubMed 26785480
- Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018. PubMed 29514064
- Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016. PubMed 28068222
- Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020. PubMed 31685720
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed 33888596
Research compounds
Related guides
Research Use Only. Not for human or veterinary use. Not dosing or medical guidance.
